View Older Stories View More Recent Stories
-
BofA Securities Upgrades Hims and Hers (HIMS) to Neutral
-
Canaccord Reiterates Buy Rating on Hims and Hers (HIMS)
-
Citi Upgrades Hims and Hers (HIMS) to Neutral
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.2 calls to 1 put as share price up 41%
-
TD Cowen: 'Wegovy Injection may be declining'
-
Needham Upgrades Hims and Hers (HIMS) to Buy
-
Nephron Upgrades Hims and Hers (HIMS) to Buy
-
BTIG Reiterates Neutral Rating on Hims and Hers (HIMS) following Novo partnership
-
Truist Reiterates Hold Rating on Hims and Hers (HIMS)
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS) amid Novo partnership
-
HIMS partners with Novo Nordisk, shifts US weight loss strategy
-
Hims soars 44% on report Novo Nordisk to sell weight-loss drugs on its platform
-
FDA issues 30 warning letters to telehealth firms over GLP-1 claims
-
Prior to Market Open: Endpoint News Reports 'HIMS’ pharmacy partner will reintroduce GLP-1 pill pulled from market'
-
Jefferies: 'We appreciate and agree with what HIMS mgmt is doing'
-
Hims and Hers (HIMS) PT Lowered to $18 at Truist Securities
-
Hims and Hers (HIMS) PT Lowered to $17 at TD Cowen Amid NT Uncertainty
-
KeyBanc Reiterates Sector Weight Rating on Hims and Hers (HIMS)
-
BTIG Downgrades Hims and Hers (HIMS) to Neutral
-
Hims and Hers (HIMS) PT Lowered to $17.50 at Leerink Partners
-
Hims and Hers (HIMS) PT Lowered to $24 at Evercore ISI
-
Hims and Hers (HIMS) PT Lowered to $12.50 at BofA Securities
-
After-hours movers: Hims & Hers Health, Keysight, Bed Bath & Beyond, Myriad Genetics, and more
-
Hims & Hers Health, Inc. (HIMS) Tops Q4 EPS by 3c, Offers Guidance
-
Hims & Hers is due to report after the bell. Here's what to watch out for.
-
Hims & Hers Health Inc. set to report Q4 earnings with guidance cut fears mounting after compounded semaglutide fallout
-
Hims & Hers Health (HIMS) stock: Should you buy the dip after massive selloff?
-
Hims and Hers (HIMS) PT Lowered to $30 at Canaccord Genuity
-
Hims and Hers (HIMS) PT Lowered to $13 at BofA Securities
-
Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
-
Needham Reiterates Hold Rating on Hims and Hers (HIMS)
-
Novo Nordisk sues Hims & Hers over compounded semaglutide products
-
Novo Nordisk jumps, Hims shares plummet after pulling $49 weight-loss pill
-
BTIG Reiterates Buy Rating on Hims and Hers (HIMS)
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.2 calls to 1 put into stopping offering access to semaglutide pill
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
-
Hims and Hers (HIMS) PT Lowered to $21 at BofA Securities
-
Hims & Hers Health (HIMS) said to stop offering weight loss pill
-
FDA moves to restrict copycat GLP-1 weight loss drugs
-
Hims & Hers stock falls after FDA warns against illegal copycat drugs
-
TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
-
Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
-
Novo Nordisk threatens legal action over Hims & Hers semaglutide pill
-
Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
-
Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'
-
Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
-
BMO Capital: 'Novo Mgmt Meetings Highlight Deep Strategic Challenges'
-
Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall
-
Hims & Hers adds compounded semaglutide pills starting at $49 monthly
-
Hims & Hers Health (HIMS) launches a copy of Wegovy pill at $49/month
